Back to search results

SPM Active® Supplementation for Adults with Obesity

This study is looking at whether a daily dietary supplement called SPM Active® can increase certain beneficial omega-3 fatty acid derivatives in adults with obesity. These derivatives are thought to help reduce inflammation. Participants will take two SPM Active® soft-gel capsules every day for 12 weeks. Researchers will measure levels of these omega-3 derivatives in your blood before and after taking the supplement. They will also ask you to complete surveys about your burnout, life satisfaction, and sleep quality to see if the supplement improves these areas. The study aims to enroll 33 adults, aged 45-60, with a body mass index (BMI) between 30 and 40 kg/m². The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 33 participants. It is a single-arm study, meaning all participants will receive the SPM Active® supplement.
What's involved
You would take two SPM Active® soft-gel capsules daily for 12 weeks. You will also provide 12-hour fasting blood samples and complete surveys at the beginning and end of the study.
Compensation
Not stated in the trial record.
Follow-up
Your blood levels and survey responses will be measured at the start of the study and again at the end of the 12-week treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06991296

Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.

Recruiting
NAAges 45–60Interventional
University of North Carolina, Chapel Hill
~33 participants
Updated 2026-02-17 on ClinicalTrials.gov
What's tested:SPM Active®

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Plasma Levels of Monohydroxylated n-3 PUFA Derivatives (14-HDHA, 17-HDHA, 18-HEPE)
Measured over Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)

Conditions

Obesity

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Saame Shaikh, PhD · PRINCIPAL_INVESTIGATOR · University of North Carolina, Chapel Hill

Who to contact

Saame R Shaikh, PhD
[email protected]
317-409-9565
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

adults, ages 45-60 years
Body mass index (BMI) between 30 and 40 kg/m\^2
Any race or ethnicity

Exclusion

Age \< 45 years or \> 60 years
pregnant or breastfeeding women
BMI \< 30 kg/m\^2 or \> 40 kg/m\^2
Diagnosed type 1 or type 2 diabetes
Active autoimmune disease, liver disease, coagulopathy, or hypothyroidism
Known allergy to fish or shellfish
Current use of any of the following medications: asthma controller therapies, anticoagulants, estrogen or testosterone, daily aspirin or NSAIDs.
Inability to give informed consent
Receiving immunomodulatory or immunosuppressant therapy
Known active malignancy or undergoing treatment for malignancy
Use of n-3 PUFA supplements or high consumption of fatty fish (\> 2 servings/week) within 3 months prior to enrollment.

What this trial measures

  • Change in Plasma Levels of Monohydroxylated n-3 PUFA Derivatives (14-HDHA, 17-HDHA, 18-HEPE)Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)

    Mean change from baseline in fasting plasma concentrations of 14-HDHA, 17-HDHA, and 18-HEPE, as quantified by liquid chromatography-mass spectrometry.